Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Cara Therapeutics, Inc. Company Profile

03:20 EDT 22nd July 2014 | BioPortfolio

News Articles [30 Associated News Articles listed on BioPortfolio]

Janney, Stifel start CARA Therapeutics at buy

Janney Capital Partners and Stifel Nicolas have initiated coverage CARA Therapeutics (NASDAQ:CARA) with “buy” ratings and a $25 fair value estimate and 12-month target price of $21, respectively....

Cara Therapeutics, Inc. [CARA] to Ring The NASDAQ Stock Market Opening Bell

ADVISORY, March 10, 2014 (GLOBE NEWSWIRE) -- What: Cara Therapeutics, Inc. [CARA], a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allev...

Cara Therapeutics doses first patient in Phase Ia/Ib trial of CR845 to treat acute, chronic pain

Enteris BioPharma, an industry leader in innovative oral dosage formulations, has announced that its development partner, Cara Therapeutics (CARA) has dosed the first subjects in a further Phase 1a/1b...

Pain management company Cara Therapeutics' IPO nets $51.2mm

Cara Therapeutics Inc. (pain management) netted $51.2mm in its initial public offering of 5mm shares at $11, the bottom end of its planned $11-13 price range.

Pain management company Cara Therapeutics' IPO nets $58.8mm

Cara Therapeutics Inc. (pain management) netted $58.8mm in its initial public offering of 5.75mm shares (including the overallotment) at $11, the bottom end of its planned $11-13 price range.

Five questions for: Cara Therapeutics CEO Derek Chalmers

Cara Therapeutics is one of 19 biotechnology firms to launch an initial public offering so far in 2014, so with $55.9m in IPO proceeds in the bank, president and CEO Derek Chalmers can focus on his co...

Trevena, Cara price IPOs

Neurology company Trevena Inc. (NASDAQ:TRVN) and pain play Cara Therapeutics Inc. (NASDAQ:CARA) both raised money in IPOs on Friday. Trevena raised $64.8 million through the sale of a bumped-up number...

Cara Therapeutics Readies Novel Analgesic For Phase III In Acute Pain

Having just completed an IPO netting nearly $59 million, Cara is seeking an end-of-Phase II meeting with FDA to design registrational trials for CR845, an intravenous selective kappa opioid receptor a...

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Label-free chemiluminescent aptasensor for platelet-derived growth factor detection based on exonuclease-assisted cascade autocatalytic recycling amplification.

Here an exonuclease III (Exo III)-assisted cascade autocatalytic recycling amplification (Exo-CARA) strategy is proposed for label-free chemiluminescent (CL) detection of platelet-derived growth facto...

Identification of human trafficking victims in dental care settings.

Trafficking in human beings (THB) is a modern form of slavery and is a well-known phenomenon throughout the European Union and beyond. After drug dealing and the weapons industry, human trafficking is...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Protecting the 'Hood Against Tobacco

Among all racial/ethnic groups, African Americans have the greatest risk of becoming ill or dying from tobacco-related diseases. Because of this disproportionate disease burden, it is part...

Companies [4 Associated Companies listed on BioPortfolio]

CARA Therapeutics

Cara possesses both near-term clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's first patented compound, CR665, has enter...

Cara Therapeutics, Inc.


Instituto de Cirugía Maxilofacial e Implantología

Me es grato darles la bienvenida a la página web del INSTITUTO DE CIRUGIA MAXILOFACIAL E IMPLANTOLOGIA.El Instituto, fundado en Mayo del 2000, tiene como objetivo el tratamiento integral médico-quir...

More Information about "Cara Therapeutics, Inc." on BioPortfolio

We have published hundreds of Cara Therapeutics, Inc. news stories on BioPortfolio along with dozens of Cara Therapeutics, Inc. Clinical Trials and PubMed Articles about Cara Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cara Therapeutics, Inc. Companies in our database. You can also find out about relevant Cara Therapeutics, Inc. Drugs and Medications on this site too.

Search BioPortfolio:

Corporate Database Quicklinks

Searches Linking to this Company Record